<p>Model Parameters.</p>

A 10-year partitioned survival model compares the cost-effectiveness of two first-line treatments for advanced hepatocellular carcinoma from the perspective of the Chinese healthcare system. The dataset, authored by XueYin Xu and last updated in May 2026, contains parameters and results from a health economic analysis based on a Phase III clinical trial. It includes total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) for a dual-agent therapy versus sorafenib.

Use Cases

• Replicate health economic models based on the described partitioned survival structure and 3-week cycle length
• Conduct sensitivity analysis on key parameters like utility values and drug costs mentioned in the description
• Benchmark incremental cost-effectiveness ratios against a willingness-to-pay threshold of 299,400 CNY
• Validate probabilistic sensitivity analysis results for oncology treatment cost-effectiveness

Strengths

• Model parameters are derived from a Phase III clinical trial, suggesting a foundation in empirical clinical data
• Analysis includes one-way and probabilistic sensitivity analyses, indicating robustness checks were performed
• The time horizon is explicitly defined as 10 years with a 4.5% discount rate

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download
• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

figshare

Collection Method

Constructed from the results of a Phase III clinical trial using a three-state partitioned survival model.

Time Range

Model horizon of 10 years.

Freshness

Last updated 2026-05-14 17:39:55; freshness should be verified

Geography

Analysis from the perspective of the Chinese healthcare system.